OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$14.12
0.59 (4.36%)
▲
5d:
+20.27%
30d:
+14.89%
90d:
-47.76%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 20, 2026
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $14.12, which is considered fair relative to its 30-day fair value range of $8.52 to $20.26.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is approaching resistance at $14.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.68 (+166.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is approaching resistance at $14.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.68 (+166.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.52 -
$20.26
Company Quality Score
59/100
(HOLD)
Options IV Signal
62th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
87.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 62th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 166.9% below Wall St target ($37.68)
Trading Range Analysis
30-Day Trading Range
$8.52 -
$20.26
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.43
(17.2%)
Support & Resistance Levels
Support Level
$10.88
Resistance Level
$14.34
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.63
Wall Street Target
$37.68
(+166.9%)
Revenue Growth (YoY)
-26.7%
Share & Embed Analysis
Last updated: July 02, 2026 10:41 PM ET
Data refreshes hourly during market hours. Next update: 11:41 PM
Data refreshes hourly during market hours. Next update: 11:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$291 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 61 BUY |
